New IPO News Of Preclinical biotech PhaseRx

New IPO News Of Preclinical biotech PhaseRx

PhaseRx, a preclinical biotech developing treatments for inherited enzyme deficiencies in the liver, filed on Monday with the SEC to raise up to $30 million in an initial public offering.

The Seattle, WA-based company was founded in 2006 and booked $0 million in sales for the 12 months ended December 31, 2015. It plans to list on the Nasdaq under the symbol PZRX. Laidlaw & Company (UK) is the sole book runner on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.